share_log

Procaps Group (NASDAQ:PROC) Shares Gap Up to $4.30

Defense World ·  Jan 29, 2023 03:32

Procaps Group S.A. (NASDAQ:PROC – Get Rating)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $4.30, but opened at $6.70. Procaps Group shares last traded at $4.48, with a volume of 13,152 shares changing hands.

Procaps Group Stock Up 0.2 %

The firm has a 50 day simple moving average of $5.55 and a two-hundred day simple moving average of $6.74.

Get Procaps Group alerts:

Procaps Group (NASDAQ:PROC – Get Rating) last released its earnings results on Monday, November 14th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.09. Procaps Group had a negative return on equity of 243.60% and a net margin of 13.82%. The firm had revenue of $110.40 million for the quarter, compared to analyst estimates of $123.90 million. Equities research analysts expect that Procaps Group S.A. will post 0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Procaps Group

Several large investors have recently bought and sold shares of PROC. Citadel Advisors LLC acquired a new position in Procaps Group in the second quarter valued at about $263,000. Millennium Management LLC grew its stake in Procaps Group by 15.9% in the second quarter. Millennium Management LLC now owns 101,430 shares of the company's stock valued at $945,000 after acquiring an additional 13,908 shares during the period. Finally, State Street Corp acquired a new position in Procaps Group in the third quarter valued at about $89,000. Institutional investors own 0.95% of the company's stock.

Procaps Group Company Profile

(Get Rating)

Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.

See Also

  • Get a free copy of the StockNews.com research report on Procaps Group (PROC)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Procaps Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procaps Group and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment